Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine

Acta Neurologica Scandinavica

Volumn 122, Issue SUPPL. 190, 2010, Pages 30-33

  Svalheim, S ^a   Luef, G ^b   Rauchenzauner, M ^b   Morkrid L ^a,c   Gjerstad, L ^a,c   Tauboll E ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CHOLESTEROL; ETIRACETAM; HIGH DENSITY LIPOPROTEIN; LAMOTRIGINE; LOW DENSITY LIPOPROTEIN;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRINKING BEHAVIOR; EPILEPSY; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHYSICAL ACTIVITY; SMOKING HABIT;

EID: 77953177684     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01372.x     Document Type: Article

References (18)

1. Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc 1996;71 : 576-586.
2. Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003;16 : 165-170.
3. Sheth RD. Metabolic concerns associated with antiepileptic medications. Neurology 2004;63 : S24-9.
4. Ding D, Wang W, Wu J et al. Premature mortality in people with epilepsy in rural China: a prospective study. Lancet Neurol 2006;5 : 823-827.
5. Nilsson L, Tomson T, Farahmand BY, Diwan V, Persson PG. Cause-specific mortality in epilepsy. A cohort study of more than 9000 patients once hospitalized for epilepsy. Epilepsia 1997;38 : 1062-1068.
6. Annegers JF, Hauser WA, Shirts SB. Heart disease mortality and morbidity in patients with epilepsy. Epilepsia 1984;25 : 699-704.
7. Cockerell OC, Johnson AL, Sander JW, Hart YM, Goodridge DM, Shorvon SD. Mortality from epilepsy: results from a prospective population-based study. Lancet 1994;344 : 918-921.
8. Gaitatzis A, Carroll K, Majeed A, Sander JW. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 2004;45 : 1613-1622.
9. Muuronen A, Kaste M, Nikkila EA, Tolppanen EM. Mortality from ischaemic heart disease among patients using anticonvulsive drugs: a case-control study. Br Med J Clin Res Ed 1985;291 : 1481-1483.
10. Isojärvi JIT, Pakarinen AJ, Myllyla VV. Serum lipid levels during carbamazepine medication: a prospective study. Arch Neurol 1993;50 : 590-593.
11. Sudhop T, Bauer J, Elger CE, Von Bergmann K. Increased high-density lipoprotein cholesterol in patients with epilepsy treated with carbamazepine: a gender-related study. Epilepsia 1999;40 : 480-484.
12. Ben-Menachem E. Levetiracetam: treatment in epilepsy. Exp Opin Pharmacother 2003;4 : 2079-2088.
13. Mintzer S, Skidmore CT, Abidin CJ et al. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol 2009;65 : 448-456.
14. Commission on classification and terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30 : 389-399.
15. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364 : 937-952.
16. Tholstrup JS, Grønbaek M, Nordestgaard BG. Alkohol intake, myocardial infarction, biochemical risk factors, and alcohol dehydrogenase genotypes. Circ Cardiovasc Genet 2009;2 : 5007-5014.
17. Livingston S. Phenytoin and serum cholesterol (letter). Br Med J 1976;1 : 586.
18. Zaccara G. Neurological comorbidity and epilepsy: implications for treatment. Acta Neurol Scand 2009;120 : 1-15.